louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03384459: Maintenance Therapy of 308-nm Excimer Laser Therapy in Patients With Vitiligo
Official title: Maintenance Therapy of 308-nm Excimer Laser Therapy in Patients With Vitiligo
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Vitiligo
Maintenance Therapy
the 308-nm Excimer Laser
Recurrence
Keywords: vitiligo
308-nm excimer laser
maintenance therapy
recurrence
Lead sponsor: The Catholic University of Korea
Sponsor class: OTHER
First posted: 2017-12-27
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Although vitiligo is difficult to cure, recurrences are frequent after treatment, and many patients suffer from concerns about recurrence as well as disease. Psoriasis, another indication for ultraviolet radiation treatment, has been established that it can safely and effectively reduce the recurrence of psoriasis through monthly maintenance therapy. The aim of this study was to evaluate the efficacy of 308-nm excimer laser therapy for the prevention of relapse in vitiligo.

Detailed description: For a total period of 12 months, perform the 308-nm excimer laser treatment once a month. Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.

An independent evaluator will obtain the score of vitiligo area (Vitiligo Extent Score) from comparing clinical photographs of before registration and after the clinical trial, and judge whether vitiligo is recurred. This study is a randomized controlled trial, and the investigators plan to compare the recurrence rates of the experimental and control groups using the Chi-squared test.

Eligibility criteria: Inclusion Criteria:

1. Patients with age of 19 years or older
2. Patients of generalized vitiligo with lesions on the trunk
3. Patients who had treated with the 308-nm excimer laser previously and achieved more than 75% lesion improvement
4. Patients who voluntarily agreed to participate in the study

Exclusion Criteria:

1. Patients under the age of 19
2. Patients with localized vitiligo and segmental vitiligo
3. Patients who are in a state of physical or mental impairment to perform treatment or pregnant
4. Patients with spreading of vitiligo lesions
5. Patients who do not want to do thie study or who refuse to write a consent form
6. Any other person deemed unsuitable for the examination at the discretion of the examiner

Primary outcomes:
measure: Recurrence of vitiligo
timeFrame: Change from Baseline area score at 12 months
Secondary outcomes:
measure: The assessment of patient satisfaction
timeFrame: at Baseline and at 12 months
Other outcomes:
Locations:
city: Suwon
country: Korea, Republic of
facility: St. Vincent's Hospital
state: Gyonggi-do
Study officials:
References:
Clinical trial NCT07006259: Effect of Bobath Therapy on Balance Alterations in Patients With Multiple Sclerosis
Official title: Effect of Bobath Therapy on Balance Alterations in Patients With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bobath Therapy
Postural Control
Virtual Reality
Home Exercise Program
Lead sponsor: Universidad Rey Juan Carlos
Sponsor class: OTHER
First posted: 2025-06-05
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the effects of a foot treatment to improve balance according to the Bobath Concept in people with Multiple sclerosis, comparing it with treatment through home exercise and with treatment from Bobath Concept combined with the use of virtual reality.

As a secondary objective, we seek to know the state of the art of Bobath therapy in Multiple Sclerosis.


Eligibility criteria: Inclusion Criteria:

1. Age: over 18 years old.
2. Have a diagnosis of multiple sclerosis, according to Mc Donald criteria at least 6 months before the start of the intervention.
3. Be able to walk independently in a closed environment with or without technical aids, having a maximum score of 6.5 on the Expanded Disability Status Scale or EDSS, according to its acronym in English:

6.5= constant bilateral help (canes, crutches or braces) to walk about 20 meters without rest. The usual functional system (FS) is equivalent to combinations with more than two FS of grade 3+.

Exclusion Criteria:

1. Participants who are not able to understand instructions,
2. Participants who are in a clinically unstable situation or who have risk factors or concomitant pathologies of the musculoskeletal system, neurological or cardiovascular, which make it difficult to carry out the treatment.
3. Participants with visual disturbances or severe upper limb involvement who therefore have difficulty using the VR glasses or performing reaching exercises with them.

Primary outcomes:
measure: Balance Evaluation Systems Test (Mini BESTest).
timeFrame: At the beginning, at the month and we would reevaluate after 15 days
Secondary outcomes:
measure: Timed Up and Go Test
timeFrame: At the beginning, at the month and we would reevaluate after 15 days
Other outcomes:
measure: Functional reach test (FRT)
timeFrame: At the beginning, at the month and we would reevaluate after 15 days
measure: Modified Fatigue Impact Scale (MFIS)
timeFrame: At the beginning, at the month and we would reevaluate after 15 days
measure: MusiQoL
timeFrame: At the beginning, at the month and we would reevaluate after 15 days
measure: Neo-plate pressure platform
timeFrame: At the beginning, at the month and we would reevaluate after 15 days
measure: Computerized dynamic posturography (PDC).
timeFrame: At the beginning, at the month and we would reevaluate after 15 days
Locations:
city: Alcorcón
country: Spain
facility: Universidad Rey Juan Carlos
state: Madrid
Study officials:
References:
Clinical trial NCT03102359: Brain Protection Effect of Selective Head Cooling and Dexmedetomidine in Patients Undergoing Liver Transplantation
Official title: Cerebral Protection Effect of Selective Head Cooling and Dexmedetomidine in Patients Undergoing Liver Transplantation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Liver Transplant; Complications
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2017-04-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators investigated in the present study whether selective head cooling and dexmedetomidine has an effect on cerebral oxygenation during liver transplantation and has cerebral protective effect in patients undergoing liver transplantation.


Eligibility criteria: Inclusion Criteria:

* Scheduled for OLT, selected from the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.
* Sign the informed consent

Exclusion Criteria:

* The patients with a history of neurological or psychiatric disorders which impair cognitive processes, including previously established de-mentia, stroke, schizophrenia and depression were excluded from the study.
* Patients diagnosed with hepatic encephalopathy or had a low Mini-Mental State Examination (MMSE) score (below 24) preoperatively.
* With concurrent diseases such as renal insufficiency, diabetes mellitus were also excluded.
* Patients were excluded if severe reperfusion syn-drome (mean arterial pressure below 60mmHg sustained over 15minutes) occurred perioperatively.

Primary outcomes:
measure: Postoperative minimal hepatic encephalopathy (MHE)
timeFrame: 14 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT06600659: A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
Official title: A Pilot Study to Establish Incidence and Characteristics of Patients at Risk for Symptomatic Hyperammonemia Secondary to Recombinant Erwinia Asparaginase
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hematopoietic and Lymphatic System Neoplasm
Acute Lymphobkastic Leukemia
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 10
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients receiving recombinant Erwinia asparaginase for treatment of malignancy

Brief summary: This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

Detailed description: PRIMARY OBJECTIVE:

I. To determine incidence of patients who develop hyperammonemia secondary to recombinant Erwinia asparaginase.

II. To characterize patients at risk for hyperammonemia secondary to recombinant Erwinia asparaginase.

OUTLINE: This is an observational study.

Patients undergo blood sample collection, complete surveys, and have their medical records reviewed on study.

Eligibility criteria: Inclusion Criteria:

* Followed by pediatric hematology/oncology
* Receiving recombinant Erwinia asparaginase for treatment of malignancy

Exclusion Criteria:

* Patients \< 1 year of age
* Patients who have previously received recombinant Erwinia asparaginase within the past two weeks

Primary outcomes:
measure: Incidence of patients who develop hyperammonemia
timeFrame: Up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic in Rochester
name: Catherine E. Martin, PharmD, RPh
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01170559: Use of Loop Recorders for Diagnosis of Palpitations in A&E
Official title: Use of Implantable Loop Recorders as a Primary Investigation of Infrequent Undiagnosed ArrhythmIa Symptoms in the Emergency Department
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Palpitations
Lead sponsor: Barts & The London NHS Trust
Sponsor class: OTHER
First posted: 2010-07-27
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Heart rhythm abnormalities underlie one of the common presenting complaints to the A\&E and out-patient departments, specifically awareness of heart beats or palpitations. Unless an ECG (electrocardiogram) tracing of the heart rhythm can be recorded while the patient is having symptoms, it is very difficult to determine the cause of the palpitations. The conventional approach is to refer these patients from the emergency departments to the Cardiology outpatients where they undergo repeated short term rhythm monitoring hoping to record the rhythm underlying the patient's complaint. Unfortunately, this often yields no results thus delaying definitive treatment and incurring extra costs of repeated investigations and A\&E presentations. This study aims to compare the ability of the conventional approach to establish a definite diagnosis compared to that of an early invasive monitoring approach with a small implantable device that records the heart rhythm at all time for up to 18 months.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Good history of episodic symptomatic sustained palpitations (sudden onset and offset, fast heart beats, may be associated with shortness of breath or dizziness)
* Terminates before presentation to hospital
* Episodes occur at a frequency of less than once every two weeks
* Never previously caught on ECG or ambulatory monitoring
* Normal resting ECG

Exclusion Criteria:

* Contraindication to ILR implantation i.e. ongoing oral anticoagulation with INR \>1.6, ongoing infection, sepsis or fever, etc.
* Palpitations suggestive of extrasystoles (single missed or dropped beats)
* Known or suspected severe valvular or myocardial heart disease

  * An audible heart murmur
  * Any abnormality on the surface ECG
* Thyrotoxicosis
* Patients who refuse an ILR when offered will not be included in either limb of the study

Primary outcomes:
measure: The primary endpoint of the study is the proportion of patients achieving a definite diagnosis in each of the two groups at the end of one year
timeFrame: 1 year
Secondary outcomes:
measure: The time taken from randomisation in the A&E to making the diagnosis (if any) in each group
timeFrame: 1 Year
measure: The cost of achieving a diagnosis in each group
timeFrame: 1 Year
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Barts and the London NHS Trust
Study officials:
affiliation: Barts and the London NHS Trust, Queen Mary University of London
name: Richard Schilling, MD, FRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03728959: Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.
Official title: Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism (KS-4-HypoPT).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypoparathyroidism
Keywords: hypoparathyroidism
Glucose-dependent insulinotropic polypeptide (GIP)
Glucagon-like peptide-2 (GLP-2)
Bone remodeling
Bone resorption
Bone formation
C-terminal telopeptide (CTX)
N-terminal propeptide of type 1 procollagen (P1NP)
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: Hvidovre University Hospital
First posted: 2018-11-02
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Maximum age (years): 76
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Hypoparathyroidism (hypoPT) is characterized by low levels of PTH.

In this study we will test the effects of a liquid meal on the bone remodeling in participants with hypoparathyroidism. Furthermore, we will test the effects of the gut hormones GIP and GLP-2.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 76
* Hypoparathyroidism

Exclusion Criteria:

* Diabetes
* Disease in the gastrointestinal tract
* Antiosteoporotic drug
* Long term steroid treatment (within the last 12 months)
* Pregnancy

Primary outcomes:
measure: Serum concentration of C-terminal telopeptide (CTX)
timeFrame: -10 to 240 minutes
measure: N-terminal propeptide of type 1 procollagen (P1NP)
timeFrame: -10 to 240 minutes
Secondary outcomes:
measure: PTH
timeFrame: -10 to 240 minutes
measure: Glucose-dependent insulinotropic polypeptide (GIP)
timeFrame: -10 to 240 minutes
measure: Glucagon-like peptide-2 (GLP-2)
timeFrame: -10 to 240 minutes
measure: Glucagon-like peptide-1 (GLP-1)
timeFrame: -10 to 240 minutes
measure: Glucose
timeFrame: -10 to 240 minutes
measure: Insulin
timeFrame: -10 to 240 minutes
measure: C-peptide
timeFrame: -10 to 240 minutes
Other outcomes:
measure: Blood pressure
timeFrame: -10 to 240 minutes
measure: Heart rate
timeFrame: -10 to 240 minutes
Locations:
city: Hvidovre
country: Denmark
facility: Hvidovre University Hospital
Study officials:
affiliation: University of Copenhagen
name: Mette Rosenkilde, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05052359: Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours
Official title: Aberrant Helix Pomatia Agglutinin Binding Glycan Expression Changes With the Phenotype of Follicular Thyroid Tumours
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Follicular Thyroid Cancer
Keywords: Glycosylation
Lead sponsor: National University Health System, Singapore
Sponsor class: OTHER
First posted: 2021-09-22
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: For this retrospective cohort study, 37 patients who underwent thyroid surgery for a thyroid follicular neoplasm between 2005 and 2018 were identified from our institutional database and their tumours, characteristics and outcomes were analysed.

Brief summary: Aberration of glycosylation is a hallmark of cancer cells, and plays an important role in oncogenesis and cancer progression, including metastasis. One of the markers of aberrant glycosylation (O-linked) is the binding of the lectin Helix pomatia agglutinin (HPA), which has been demonstrated in a wide range of human cancers, especially in tumours with a more aggressive phenotype. Data on the role of HPA within follicular neoplasms of the thyroid gland are currently lacking, therefore we sought to investigate possible changes in cell surface glycosylation associated with this type of neoplasms.

Detailed description: Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)). Sections were scored as positive when ≥5% of cancer cells labelled positive, and scored as negative when \<5% labelled positive for HPA binding. Assessments of HPA-binding were performed by two observers, who were blinded to the identity of the sample, and their results were compared.

Eligibility criteria: Inclusion Criteria:

* For this retrospective cohort study, 37 patients who underwent thyroid surgery for a thyroid follicular neoplasm between 2005 and 2018 were identified from our institutional database and their tumours, characteristics and outcomes were analysed.

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Positivity of HPA-labelling
timeFrame: between 2005 and 2018
Secondary outcomes:
measure: HPA-binding and other tumor markers
timeFrame: between 2005 and 2018
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National University Hospital
Study officials:
References:
Clinical trial NCT04562259: Verification of Kimmerle's Anomaly by X-ray Methods of Research
Official title: Verification of Kimmerle's Anomaly by X-ray Methods of Research
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Kimmerle's Anomaly
Lead sponsor: Samarkand State Medical Institute
Sponsor class: OTHER
First posted: 2020-09-24
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients of all ages will be examined, directed by doctors for computed tomography of the brain with the capture of the upper cervical spine and the cervical spine. with complaints of headache, dizziness, pain in the cervical region

Brief summary: Kimmerle's anomaly is a bony bridge over the posterior arch of the first cervical vertebra that forms a bony ring. The vertebral artery passes through the opening. This bone bridge could theoretically be an extravasal compression of the artery and disrupt the normal blood flow to the brain. Evaluating the data of X-ray methods, determine the frequency of occurrence and types of Kimmerle anomaly.

Detailed description: It is planned to conduct an examination of 30 patients on the basis of the Department of Radiation Diagnostics and Therapy of the Samarkand State Medical Institute. Patients of all ages will be examined, directed by doctors for computed tomography of the brain with the capture of the upper cervical spine and the cervical spine. with complaints of headache, dizziness, pain in the cervical region Among those who have passed the study, it is necessary to identify patients with Kimmerle's anomaly and determine the age at which it often occurs, whether it is a congenital pathology or the result of degenerative-dystrophic changes. It is also planned to calculate the frequency of occurrence among the population, the type of this pathology (complete and incomplete bone bridge, right-sided and left-sided location), the size of the hole formed. The condition of the posterior parts of the brain will be assessed in the presence of Kimmerle's anomaly on a CT scan.

Eligibility criteria: Inclusion Criteria:

* Patients with Kimmerle's anomaly

Exclusion Criteria:

* patients in whom the structure of the first cervical vertebra is not clearly visible

Primary outcomes:
measure: In patients with Kimmerle anomaly, determine the types of forms of this pathology
timeFrame: up to 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Samarkand
country: Uzbekistan
facility: Samarkand State Medical Institute
Study officials:
affiliation: Samarkand State Medical Institute
name: Gulshod Mardieva, docent
role: STUDY_DIRECTOR
References:
Clinical trial NCT06128759: Focusing on the Maryam's Flower During the Birth
Official title: The Effect of Focusing on the Maryam's Flower During the Birth Process on Labor Pain, Labor Duration and Perceived Fatigue in Birth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Labor Pain
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2023-11-13
Enrollment: 126
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: To determine the Effect of Focusing on the Virgin Mary Flower during the Birth Process on Labor Pain, Labor Duration and Perceived Fatigue in Birth.

Method: The study will be completed in a randomized controlled manner with a total of 126 primiparous pregnant women, 63 in the experimental group and 63 in the control group. Pregnant women in the experimental group will focus on the Virgin Mary flower in the water-filled jar and imagine that their uterus and birth path are opening like the branches of the Virgin Mary flower that blooms as labor pains come. There will be no intervention in the control group other than routine midwifery care. Research data will be collected with the Pregnant Introduction and Birth Process Follow-up Form, Visual Analog Scale, and Visual Similarity Scale for Fatigue.

Detailed description: Design and Settings: This randomized controlled experimental study will conducted in the delivery room of the, Turkey between the dates of November 2023 and April 2024

Eligibility criteria: Inclusion Criteria:

* Being 18 years or older,
* being in 37-42 weeks of pregnancy,
* being primiparous,
* having a single healthy fetus,
* cervical dilatation not more than 3 cm.the one which,
* in the first stage of labor,
* Does not have any complications preventing vaginal birth,
* volunteer women who do not have disabilities in communication and perception

Exclusion Criteria:

* maternal and fetal complications
* pregnant with assisted reproductive techniques,
* having a presentation anomaly,
* having a twin pregnancy,
* electing cesarean section,
* Women whose cervical dilatation exceeds 3 cm and who are not willing to participate in the study

Primary outcomes:
measure: severity of labor pain by VAS
timeFrame: immediately after intervention
measure: Visual Similarity Scale for Fatigue
timeFrame: immediately after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Ondokuz Mayis University
Study officials:
affiliation: Ondokuz Mayıs University
name: Sümeyye BAL
role: STUDY_CHAIR
affiliation: Ondokuz Mayıs University
name: Sümeyye BAL
role: PRINCIPAL_INVESTIGATOR
References: